The limited therapeutic options available for hepatocellular carcinoma (HCC) make mandatory to find alternative effective treatments for this tumor. Based on the recent finding that systemic or local hypothyroidism is associated with HCC development in humans and rodents, we investigated whether the thyroid hormone triiodothyronine (T3) could inhibit the progression of hepatocellular carcinomas (HCCs).
Kowalik, M.a., Puliga, E., Cabras, L., Sulas, P., Petrelli, A., Perra, A., et al. (2020). Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming. JOURNAL OF HEPATOLOGY, 1159-1169 [10.1016/j.jhep.2019.12.018].
Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming
Sanchez-Martin, Carlos;
2020-01-01
Abstract
The limited therapeutic options available for hepatocellular carcinoma (HCC) make mandatory to find alternative effective treatments for this tumor. Based on the recent finding that systemic or local hypothyroidism is associated with HCC development in humans and rodents, we investigated whether the thyroid hormone triiodothyronine (T3) could inhibit the progression of hepatocellular carcinomas (HCCs).| File | Dimensione | Formato | |
|---|---|---|---|
|
Kowalik et al.pdf
solo utenti autorizzati
Licenza:
Copyright dell'editore
Dimensione
686.81 kB
Formato
Adobe PDF
|
686.81 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
